IDH1 mutation is associated with improved overall survival in patients with glioblastoma: a meta-analysis

Cheng, Hongbin; Yue, Wu; Xie, Chen; Zhang, Ruyou; Hu, Shaoshan; Wang, Zhi

doi:10.1007/s13277-013-0934-5

Cited by 51 publications

(34 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Specifically, it was shown that IDH1 mutations associated with prolonged survival of GBM patients [9]. In this study we assessed the R132H mutation of IDH1 by immunohistochemistry.…”

Section: Resultsmentioning

confidence: 99%

“…Here, we combined FZD7 with MGMT or IDH1, as these markers were shown to associate with the survival of GBM patients in previous [8, 9] and present (Figures 3–4) studies. We found that FZD7/MGMT combination was a strong independent predictor of poor survival in GBM patients, with twice as high hazard ratios compared to FZD7 alone.…”

Section: Discussionmentioning

confidence: 99%

“…The objective of this study was to determine the expression and prognostic value of FZD7 in patients with primary GBM. Furthermore, we sought to identify novel strategies for a more accurate prognosis in these patients by analyzing FZD7 in combination with the previously-described markers MGMT (O-6-methylguanine-DNA methyltransferase) promoter methylation [8] and IDH1 (isocitrate dehydrogenase 1) mutation status [9]. As several studies described the sexually-dimorphic expression of cancer biomarkers including MGMT [10–12], we additionally tested whether our markers exhibited sex-specific differences in relationship to the overall survival of GBM patients.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Sex-specific clinicopathological significance of novel (Frizzled-7) and established (MGMT, IDH1) biomarkers in glioblastoma

et al. 2016

View full text Add to dashboard Cite

BackgroundThe Wnt receptor Frizzled-7 (FZD7) promotes tumor progression and can be currently targeted by monoclonal antibody therapy. Here, we determined the prognostic value of FZD7 for the overall survival of glioblastoma (GBM) patients, both as individual marker and taken in combination with the previously-described markers MGMT and IDH1. Additionally, we tested whether these markers (alone or in combination) exhibited sex-specific differences.ResultsHigh levels of FZD7 (FZD7high) associated with shorter survival in GBM patients; however, FZD7high was a significant predictor of poor survival only in male patients. Mutation of IDH1 significantly associated with longer survival in male but not female patients. Methylated MGMT promoter significantly associated with longer survival only in female patients. Combination of FZD7 with MGMT enhanced the prognostic accuracy and abrogated the sex differences observed upon single marker analysis. Combination of FZD7 with IDH1 was a significant predictor of survival in male GBM patients only.Materials and MethodsThree independent cohorts of patients with primary GBM (n=120, n=108 and n=105, respectively) were included in this study. FZD7 and IDH1 were assessed by immunohistochemistry in tissue microarrays. MGMT promoter methylation was determined by methylation-specific polymerase chain reaction. Survival analysis was performed by Kaplan-Meier estimate, log-rank test and Cox proportional hazard regression.ConclusionsOur study identifies novel individual and combination markers with prognostic and, possibly, therapeutic relevance in GBM. Furthermore, our findings substantiate the importance of sexual dimorphism in this type of cancer.

show abstract

“…Specifically, it was shown that IDH1 mutations associated with prolonged survival of GBM patients [9]. In this study we assessed the R132H mutation of IDH1 by immunohistochemistry.…”

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Sex-specific clinicopathological significance of novel (Frizzled-7) and established (MGMT, IDH1) biomarkers in glioblastoma

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Recently, tumor molecular markers have been identified as better predictors of growth kinetics than classical histology. Specifically, patients with mutation of the isocitrate dehydrogenase 1 ( IDH1 ) gene [2] exhibit a marked survival benefit over patients with the wild-type tumor, independent of age and histologic grading [3, 4]. Such survival differences are believed to reflect growth characteristics unique to IDH1 subtypes.…”

Section: Introductionmentioning

confidence: 99%

The effect of IDH1 mutation on the structural connectome in malignant astrocytoma

et al. 2016

View full text Add to dashboard Cite

Mutation of the IDH1 gene is associated with differences in malignant astrocytoma growth characteristics that impact phenotypic severity, including cognitive impairment. We previously demonstrated greater cognitive impairment in patients with IDH1 wild type tumor compared to those with IDH1 mutant, and therefore we hypothesized that brain network organization would be lower in patients with wild type tumors. Volumetric, T1-weighted MRI scans were obtained retrospectively from 35 patients with IDH1 mutant and 32 patients with wild type malignant astrocytoma (mean age = 45 ± 14 years) and used to extract individual level, gray matter connectomes. Graph theoretical analysis was then applied to measure efficiency and other connectome properties for each patient. Cognitive performance was categorized as impaired or not and random forest classification was used to explore factors associated with cognitive impairment. Patients with wild type tumor demonstrated significantly lower network efficiency in several medial frontal, posterior parietal and subcortical regions (p < 0.05, corrected for multiple comparisons). Patients with wild type tumor also demonstrated significantly higher incidence of cognitive impairment (p = 0.03). Random forest analysis indicated that network efficiency was inversely, though nonlinearly associated with cognitive impairment in both groups (p < 0.0001). Cognitive reserve appeared to mediate this relationship in patients with mutant tumor suggesting greater neuroplasticity and/or benefit from neuroprotective factors. Tumor volume was the greatest contributor to cognitive impairment in patients with wild type tumor, supporting our hypothesis that greater lesion momentum between grades may cause more disconnection of core neurocircuitry and consequently lower efficiency of information processing.

show abstract

“…To improve patient's survival, it is important for us to identify some molecular markers of prognosis which may help us select the best suitable therapeutic strategies. Currently, several good biomarkers for the survival of glioma patients have been found, which are very helpful for us to predict patients' prognosis [14,[33][34][35]. Mutations in PTEN gene are correlated with poorer prognosis of glioma patients [35], while isocitrate dehydrogenase 1 (IDH1) mutation is associated with better prognosis of glioma patients [14].…”

Section: Discussionmentioning

confidence: 99%

Association of Telomerase Reverse Transcriptase Promoter Mutations with the Prognosis of Glioma Patients: a Meta-Analysis

Wang

et al. 2015

Mol Neurobiol

View full text Add to dashboard Cite

Previous studies have found that telomerase reverse transcriptase (TERT) has vital roles in the development of malignant diseases including glioma. The occurrence of TERT promoter mutations in gliomas is frequent. So far, several studies on the association between TERT promoter mutations and prognosis of gliomas had been published, but the conclusion was still not uncertain. The aim of the present meta-analysis was to assess the association between TERT promoter mutations and survival of glioma patients by pooling data from published studies. PubMed, Embase, and Web of Science were searched for articles on the association between TERT promoter mutations and survival of glioma patients until June 30, 2015. Hazard ratios (HR) and the 95% confidence intervals (CIs) were utilized to analyze the prognosis of glioma patients with TERT promoter mutations. Heterogeneity of included studies was assessed using Cochrane's Q test and I (2) method. Eleven studies with a total of 3,444 glioma patients were finally included into the meta-analysis. Nine studies reported the HRs adjusting for other confounding factors. Meta-analysis of total 11 studies suggested that TERT promoter mutations were significantly associated with worse prognosis of patients with gliomas (HR = 2.07, 95% CI = 1.58-2.71, P < 0.00001). Meta-analysis of nine studies with adjusted outcomes suggested that TERT promoter mutations were independently associated with worse prognosis of patients with gliomas (HR = 2.28, 95% CI = 1.72-3.01, P < 0.00001). In conclusion, TERT promoter mutation is a promising biomarker for predicting worse prognosis for patients with gliomas. More prospective well-designed cohort studies are needed to further validate its prognostic role in gliomas.

show abstract

IDH1 mutation is associated with improved overall survival in patients with glioblastoma: a meta-analysis

Cited by 51 publications

References 26 publications

Sex-specific clinicopathological significance of novel (Frizzled-7) and established (MGMT, IDH1) biomarkers in glioblastoma

Sex-specific clinicopathological significance of novel (Frizzled-7) and established (MGMT, IDH1) biomarkers in glioblastoma

The effect of IDH1 mutation on the structural connectome in malignant astrocytoma

Association of Telomerase Reverse Transcriptase Promoter Mutations with the Prognosis of Glioma Patients: a Meta-Analysis

Contact Info

Product

Resources

About